聚乙二醇4000散剂在肛肠病术后的应用

为探讨聚乙二醇4000散剂在肛肠病术后的应用效果,选择200例肛肠病患者,随机分为观察组与对照组各100,例,观察组100例加服聚乙二醇4000散剂,对照组100例采用常规综合疗法。观察两组腹胀及排便情况。结果显示,排便正常观察组为81．5％,对照组为52．4％,两组差异有统计学意义（P〈0．01）。结果表明,聚乙二醇4000散剂可促进肛肠病术后胃肠功能恢复及纠正术后排便困难,其疗效显著。     

生物反馈联合聚乙二醇口服治疗出口梗阻型便秘32例临床观察

为探讨生物反馈联合药物疗法治疗出口梗阻型便秘（OOC）的疗效,对32例OOC患者进行生物反馈训练治疗,每次20～30min。每周5次,同时予聚乙二醇4000散剂口服,每次10g,2次／d。2周为一疗程,治疗2个疗程。随访3个月对治疗前后患者排便改善情况、便秘积分结果、肛门直肠测压结果进行对比分析。结果显示,32例患者中,显效11例,有效14例,无效7例,总有效率78．12％。治疗后,患者排便频率、排便时间、粪便性状、排便用力程度、排便不尽感评分较治疗前均明显下降;且直肠肛门抑制反射的最小松弛容积、肛管静息压、仞始便意、最大耐受量各值均较治疗前下降,最大缩榨压明显提高。结果表明,生物反馈联合聚乙二醇4000散剂口服能有效地改善OOC患者的排便困难症状。     

芪术疏肝方对气秘型慢性功能性便秘患者生活质量的干预及疗效

为观察芪术疏肝方干预治疗气秘型慢性功能性便秘患者的临床疗效及生活质量改善情况,将60例气秘型慢性功能性便秘患者随机分为治疗组和对照组,每组30例,治疗组采用芪术疏肝方口服治疗,对照组采用聚乙二醇4000散口服治疗。分别于治疗前、治疗2周、4周及停药后第4周观察和评估患者症状体征等情况。结果显示,治疗组在总体疗效、改善症状、治疗前后便秘患者生活质量、心理状况评定等方面均优于对照组（P〈0．05）。结果表明,芪术疏肝方能有效改善气秘型慢性功能性便秘患者的排便功能,舒缓患者的焦虑心理,提高患者的整体生活质量,对气秘型慢性功能性便秘患者具有较好的疗效。     

复方阿嗪米特联合聚乙二醇4000治疗老年慢性功能性便秘36例的体会

目的观察复方阿嗪米特联合聚乙二醇4000治疗老年慢性功能性便秘的疗效。方法对58例满足入选标准者,随机分为治疗组36例,给予聚乙二醇400010mg/次,2次/d;复方阿嗪米特2片,3次/d,饭后服用。对照组22例,复方阿嗪米特2片,3次/d,治疗4周。观察2组疗效。结果治疗组总有效率99.9%,对照组总有效率54.5%(P0.05);2组比较,治疗组优于对照组,差异有统计学意义(P0.05)。结论复方阿嗪米特联合聚乙二醇4000是治疗老年慢性功能性便秘较好的方法。     

综合疗法治疗肛肠病术后便秘168例临床观察

为观察中药辨证调服、苦参汤熏洗坐浴、耳穴压豆结合西药聚乙二醇4000口服治疗肛肠病术后便秘的临床疗效,将337例肛肠病术后便秘患者随机分为两组,治疗组168例采用中药辨证调服、苦参汤熏洗坐浴、耳穴压豆结合西药聚乙二醇4000口服治疗;对照组169例采用西药聚乙二醇4000口服,1：5000PP液便后坐浴治疗。结果显示,治疗组在首次排便时间、排便顺畅情况、肛门疼痛、创口水肿及创面愈合时间方面疗效明显优于对照组（P〈0．05）。结果表明,综合疗法治疗肛肠病术后便秘的疗效明显优于单纯西药治疗。     

三联法加心理干预治疗便秘型肠易激综合征的临床观察

摘要为探讨莫沙必利加补脾益肠丸和培菲康三联法配合心理干预治疗便秘型肠易激综合征（IBS-C）的疗效,根据罗马Ⅲ标准确诊IBS-C型患者100例,并将其分成两组进行随机对比试验,每组50例。治疗组口服莫沙必利加补脾益肠丸和培菲康,并对50例患者进行心理干预;对照组单纯口服莫沙必利,两组均治疗4周为1个疗程。结果显示,治疗1个疗程后两组总有效率治疗组明显高于对照组（92．0％VS74．0％,P〈0．05）。两组腹痛缓解情况在第1、2周末的比较差异无统计学意义（P〉0．05）,第3、4周末两组差异有统计学意义（P〈0．05）,而排便频率和粪便性状在第1、2、3、4周末,两组比较差异均有统计学意义（P〈0．05）。结果表明,莫沙必利加补脾益肠丸和培菲康三联法配合心理干预治疗IBS-C较单纯口服莫沙必利效果明显。     

聚乙二醇4000防治肛肠病术后大便困难的疗效观察

目的探讨聚乙二醇4000（长松）防治肛肠病术后大便困难的临床疗效。方法将121例患者按入院顺序分为2组,治疗组61例,术后每天睡前服聚乙二醇4000散剂10g,1次/d,对照组60例,术后每天睡前服麻仁九6g,1次/d。观察两组患者服药后第1次排便距服药的时间、术后第2～5d两组患者大便通畅及排便时肛门疼痛情况。结果两组患者在服药后第1次排便距服药的时间方面有差异有统计学意义（P〈0.05）,治疗组优于对照组。术后第2～5d大便通畅及排便时肛门疼痛情况差异无统计学意义（P〉0.05）。结论聚乙二醇4000能有效防治肛肠病术后大便困难。     

补中益气汤加味治疗脾虚气弱型便秘30例疗效观察

为观察补中益气汤加味治疗脾虚气弱型便秘的临床疗效,治疗组30例口服中药补中益气汤加味,对照组30例口服两药福松（聚乙二醇4000）,治疗2周后两组进行疗效比较。结果显示,两组有效率比较无统计学意义（P〉0．05）;但治疗组在用药后排便费力与排便不尽感方面优于对照组（P〈0．05）。结果表明,补中益气汤加味治疗脾虚气弱型便秘的临床疗效满意。     

灵菇胶囊与灵菇合剂治疗功能性便秘的临床研究

为验证灵菇合剂和胶囊剂型对功能性便秘的临床疗效、安全性及耐受性,为功能性便秘（虚证型）患者提供一种新型药物,我们将63例功能性便秘患者分为治疗组与对照组,治疗组32例采用灵菇胶囊口服,3次／d,4粒／次,对照组31例采用灵菇合剂口服,3次／d,10ml／次。1个疗程后通过对患者一般体检项目及排便间隔时间、便质、排便费力情况、中医证候相关症状、舌象及脉象的变化、胃肠道反应等进行疗效评定。结果显示,治疗组总有效率93．8％,对照组总有效率90．3％（P〉0．05）,灵菇胶囊改善患者大便干结、排便费力、排便不尽感等症状疗效比较明显,而且治疗组服药后无腹痛、恶心、头晕及水泻样大便等不良反应。结果表明,剂型改良后的灵菇胶囊疗效肯定,患者治疗过程中亦无明显的不良反应;胶囊型药物具有口味淡香,利于贮存、运输,方便携带及服用等特点。     

三联法加心理干预治疗腹泻型肠易激综合征的疗效观察

为探讨三联法加心理干预治疗腹泻型肠易激综合征（IBS-D）的临床疗效,将160例IBS-D患者随机分为两组,各80例,一组患者口服补脾益肠丸、酪酸梭菌活菌片和谷维素（即三联法）,同时行心理干预治疗（治疗组）,另一组患者单纯口服补脾益肠丸治疗（对照组）。两组均以4周为一疗程,6个疗程后评价疗效。结果显示,治疗组显效69例,有效9例,无效2例,总有效率为97．5％（78／80）;对照组显效32例,有效30例,无效18例,总有效率为77．5％（62／80）。治疗组总有效率明显高于对照组,P〈0．05。结果表明,三联法加心理干预治疗IBS-D疗效满意。     

润肠通便汤治疗便秘125例临床观察

为观察润肠通便汤治疗便秘的临床疗效,将所观察的241例患者分为治疗组125例,对照组116例。治疗组服用润肠通便汤,对照组服用聚乙二醇4000散剂（福松）。结果显示,治疗组总有效率为83．2％,对照组总有效率为66．4％,两组疗效比较有非常显著性差异（P〈0．01）。结果表明,润肠通便汤治疗便秘有较好的疗效。     

手足口病采用酪酸梭菌活菌散辅助治疗的临床效果分析

目的探讨酪酸梭菌活菌散治疗手足口病的临床疗效。方法选取我院2012年6月-2013年12月收治的80例手足口病患儿为研究对象,将其按照时间的顺序平均分成A组与B组,各50例。A组患儿给予酪酸梭菌活菌散治疗,B组患儿给予常规手足口病疗法,观察两组临床治疗效果。结果A组患儿临床治疗的起效时间、疱疹消失时间、食欲正常时间、体温恢复正常时间等均较B组短,差异均具有统计学意义（P〈0．05）;A组患儿临床治疗总有效率为98．0％;B组患儿总有效率为76．0％,A组患者临床效果明显优于B组,差异具有统计学意义（P〈0．05）;两组患儿均未发生较严重的不良反应。结论酪酸梭菌活菌散治疗手足口病的临床疗效较为显著,能在较短的时间内改善患者临床症状,值得应用推广。     

Efficacy of polyethylene glycol 4000 on constipation of posttraumatic bedridden patients

Objective：To investigate the efficacy and safety of polyethylene glycol 4000 （Forlax（R）） on adult patients with functional constipation due to posttraumatic confinement to bed.Methods： A total of 201 posttraumatic bedridden patients were studied in this prospective,open-labeled, singlegroup study. Polyethylene glycol 4000 was administered orally for 14 days and the dosage was adjusted according to the Bristol stool types. Demographic characteristics, disease status, treatment period and factors affecting clinical outcome, especially the concomitant medications, were recorded.Results：After administration of polyethylene glycol 4000, 194 cases （96.52%） showed remission of constipation,including 153 （76.12%）persistent remission. The average defecation frequency increased significantly after treatment and the percentage of patients with stools of normal types （Bristol types 3-5） increased as well. Genders, ages and concomitant medications showed no significant influence on the persistent remission rate. After consecutive treatment for two weeks, patients with slight movement showed a significantly higher remission rate than those without movement （95% vs 80%）. At the end of treatment, most accompanying symptoms were relieved obviously. Patients with a medical history of constipation or ever taking laxatives showed a lower remission rate. Sixty cases （29.85%） developed diarrhea during the observational period, among whom 6 （10%） withdrew from the clinical observation voluntarily at the first onset of diarrhea. Two cases suffered from abdominal pain.Conclusions：Polyethylene glycol 4000 （Forlax（R）） has efficacy on functional constipation in posttraumatic bedridden patients. Furthermore, patients with milder symptoms,more movement in bed, and longer duration of treatment but without accompanying symptoms can achieve a higher remission rate.     

Efficacy of polyethylene glycol 4000 on constipation of posttraumatic bedridden patients

Objective:To investigate the efficacy and safety of polyethylene glycol 4000 (Forlax(R)) on adult patients with functional constipation due to posttraumatic confinement to bed.Methods: A total of 201 posttraumatic bedridden patients were studied in this prospective,open-labeled, singlegroup study. Polyethylene glycol 4000 was administered orally for 14 days and the dosage was adjusted according to the Bristol stool types. Demographic characteristics, disease status, treatment period and factors affecting clinical outcome, especially the concomitant medications, were recorded.Results:After administration of polyethylene glycol 4000, 194 cases (96.52%) showed remission of constipation,including 153 (76.12%)persistent remission. The average defecation frequency increased significantly after treatment and the percentage of patients with stools of normal types (Bristol types 3-5) increased as well. Genders, ages and concomitant medications showed no significant influence on the persistent remission rate. After consecutive treatment for two weeks, patients with slight movement showed a significantly higher remission rate than those without movement (95% vs 80%). At the end of treatment, most accompanying symptoms were relieved obviously. Patients with a medical history of constipation or ever taking laxatives showed a lower remission rate. Sixty cases (29.85%) developed diarrhea during the observational period, among whom 6 (10%) withdrew from the clinical observation voluntarily at the first onset of diarrhea. Two cases suffered from abdominal pain.Conclusions:Polyethylene glycol 4000 (Forlax(R)) has efficacy on functional constipation in posttraumatic bedridden patients. Furthermore, patients with milder symptoms,more movement in bed, and longer duration of treatment but without accompanying symptoms can achieve a higher remission rate.     

Efficacy of polyethylene glycol 4000 on constipation of posttraumatic bedridden patients

Objective:To investigate the efficacy and safety of polyethylene glycol 4000 (Forlax(R)) on adult patients with functional constipation due to posttraumatic confinement to bed.Methods: A total of 201 posttraumatic bedridden patients were studied in this prospective,open-labeled, singlegroup study. Polyethylene glycol 4000 was administered orally for 14 days and the dosage was adjusted according to the Bristol stool types. Demographic characteristics, disease status, treatment period and factors affecting clinical outcome, especially the concomitant medications, were recorded.Results:After administration of polyethylene glycol 4000, 194 cases (96.52%) showed remission of constipation,including 153 (76.12%)persistent remission. The average defecation frequency increased significantly after treatment and the percentage of patients with stools of normal types (Bristol types 3-5) increased as well. Genders, ages and concomitant medications showed no significant influence on the persistent remission rate. After consecutive treatment for two weeks, patients with slight movement showed a significantly higher remission rate than those without movement (95% vs 80%). At the end of treatment, most accompanying symptoms were relieved obviously. Patients with a medical history of constipation or ever taking laxatives showed a lower remission rate. Sixty cases (29.85%) developed diarrhea during the observational period, among whom 6 (10%) withdrew from the clinical observation voluntarily at the first onset of diarrhea. Two cases suffered from abdominal pain.Conclusions:Polyethylene glycol 4000 (Forlax(R)) has efficacy on functional constipation in posttraumatic bedridden patients. Furthermore, patients with milder symptoms,more movement in bed, and longer duration of treatment but without accompanying symptoms can achieve a higher remission rate.     

畅尔舒方治疗泻药性便秘的疗效观察

为研究畅尔舒方治疗泻药性便秘的临床疗效，将泻药性便秘患者分为观察组80例和对照组74例。观察组予畅尔舒方口服．对照组予麻仁软胶囊口服，20d为1个疗程。结果显示．观察组显效率为82．5％，对照组为51．4％（P〈0．05）。排便蹲厕时间过长消除率、排便困难感消除率观察组均明显优于对照组（P〈0．05）。结果表明．畅尔舒方对泻药性便秘有确切疗效。